



## TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

April 22, 2024

WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27<sup>th</sup> Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually.

### Oral Presentation Details:

**Title:** Discovery of Tumor Reactive TCRs and Their Cognate Antigenic Targets via High-Throughput Functional Screening

**Presenter:** Candace Perullo

**Abstract Number:** 419

**Session Title:** Targeted Gene and Cell Therapy II

**Session Date/Time:** Saturday, May 11; 10:15 a.m. - 12:00 p.m. Eastern Time

**Presentation Time:** 11:15 - 11:30 a.m. Eastern Time

**Location:** Room 318-323

### Poster Presentation Details:

**Title:** Nonclinical Development of T-Plex Component TSC-204-A0101: A Natural TCR-T Cell Therapy for the Treatment of MAGE-A1- and HLA-A\*01:01-Positive Cancers

**Presenter:** Shazad Khokhar, Ph.D.

**Abstract Number:** 834

**Session Title:** Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies

**Session Date/Time:** Wednesday, May 8; 12:00 p.m. Eastern Time

**Location:** Exhibit Hall

**Title:** Non-Clinical Development of T-Plex Component TSC-201-B0702: A TCR-T Cell Therapy Directed to a Novel HLA-B\*07:02 Restricted MAGE-C2 Epitope for the Treatment of Solid Tumors

**Presenter:** Hannah Bader, Ph.D.

**Abstract Number:** 835

**Session Title:** Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies

**Session Date/Time:** Wednesday, May 8; 12:00 p.m. Eastern Time

**Location:** Exhibit Hall

**Title:** Trial in Progress: A Phase 1, First in Human Clinical Trial for T-Plex, a Multiplexed, Enhanced T Cell Receptor-Engineered T Cell Therapy (TCR-T) for Solid Tumors

**Presenter:** Dawn Pinchasik, M.D.

**Abstract Number:** 1900

**Session Title:** Friday Posters: Cell Therapy and Cell-Based Gene Therapy Trials

**Session Date/Time:** Friday, May 10; 12:00 p.m. Eastern Time

**Location:** Exhibit Hall

**Title:** Trial in Progress: A Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell Transplantation

**Presenter:** Michelle Matzko, M.D., Ph.D.

**Abstract Number:** 1901

**Session Title:** Friday Posters: Cell Therapy and Cell-Based Gene Therapy Trials

**Session Date/Time:** Friday, May 10; 12:00 p.m. Eastern Time

**Location:** Exhibit Hall

A copy of the presentation materials will be added to the "[Publications](#)" section of the Company's website at [tscan.com](https://tscan.com) once presentations have concluded.

### About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company's lead TCR-T candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex therapeutic

TCR-Ts for patients with a variety of cancers.

**Contacts**

Heather Savelle  
TScan Therapeutics, Inc.  
VP, Investor Relations  
857-399-9840  
[hsavelle@tscan.com](mailto:hsavelle@tscan.com)

Maghan Meyers  
Argot Partners  
212-600-1902  
[TScan@argotpartners.com](mailto:TScan@argotpartners.com)